Candel Therapeutics (CADL) Stifel 2026 Targeted Oncology Virtual Forum summary

Corporate and strategic overview

• Focus on viral immunotherapies for hard-to-treat solid tumors, including prostate, pancreatic, lung cancers, and glioblastoma.

• Two investigational medicines in clinical development, both with proof of concept: aglatimagene and linoserpaturev.

• Leadership team assembled with decades of drug discovery and development experience.

• Strong external advisory board with renowned experts and Nobel laureates.

• Financial position described as stable, with runway extending to commercialization.

Clinical development and trial results

• Aglatimagene is a gene therapy delivered via simple outpatient procedure, aiming for in situ immunization and individualized anti-tumor response.

• Phase III trial in localized prostate cancer met its primary endpoint (disease-free survival) after 11 years, with statistically significant results.

• Disease-free survival defined rigorously, including biopsy-confirmed recurrence, imaging, metastases, or death from any cause.

• Two-year biopsy used as a gold standard, highly predictive of long-term outcomes.

• Recent data update with median 58 months follow-up confirmed and strengthened earlier results, showing hazard ratio of 0.61 and p-value of 0.0031 for disease-free survival.

Clinical significance and market feedback

• Key opinion leaders and market research indicate unanimous support for adoption among urologists and radiation oncologists.

• Lower incidence and delayed onset of metastases observed, especially in intermediate-risk patients (85% of trial population).

• Longer time to salvage anti-cancer therapy, reducing need for long-term hormone therapy.

• No increase in serious adverse events; treatment is well-tolerated.